Everolimus as first-line therapy in nonrapidly progressive metastatic castration-resistant prostate cancer (mCRPC): A multicenter phase II trial (SAKK 08/08)

This article has no abstract
Epistemonikos ID: c5f2b45a217ded89b873159f13a24fd0ca2928d0
First added on: Feb 04, 2025